Targetable micelleplex hydrogel for long-term, effective, and systemic siRNA delivery.

Area of Science:

• Biomaterials Science
• Nanotechnology
• Gene Therapy

Background:

• Systemic delivery of small interfering RNA (siRNA) faces challenges including rapid clearance and fluctuation in serum levels, necessitating frequent administration.
• Existing siRNA delivery systems often struggle to achieve sustained therapeutic effects and targeted delivery, limiting their clinical applicability.
• Overcoming these limitations is crucial for developing effective long-term gene silencing therapies.

Purpose of the Study:

• To develop a novel, targetable micelleplex hydrogel system for efficient systemic siRNA delivery.
• To create a hydrogel capable of controlled release, overcoming the drawbacks of multiple administrations.
• To evaluate the in vivo anti-tumor efficacy and duration of gene silencing achieved by the micelleplex hydrogel.

Main Methods:

• Development of micelleplexes, formed by complexes of polymeric micelles and siRNAs.
• Formulation of a hydrogel capable of encapsulating and enabling controlled release of micelleplexes after subcutaneous injection.
• In vivo evaluation in a tumor model to assess micelleplex accumulation, gene silencing, and anti-tumor effects.

Main Results:

• The micelleplex hydrogel demonstrated sustained release of micelleplexes after a single subcutaneous injection.
• Released micelleplexes selectively accumulated in tumor tissues.
• Significant anti-tumor effects were observed due to prolonged gene silencing, with therapy duration controllable by hydrogel properties.

Conclusions:

• The developed micelleplex hydrogel is an efficient material for systemic siRNA delivery, functioning as a targetable gene carrier.
• This system overcomes the limitations of frequent administration associated with conventional siRNA carriers.
• The micelleplex hydrogel holds promise as an effective strategy for long-term systemic gene silencing and cancer therapy.